Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ Gold
search
Subscribe
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ Gold
Subscribe
FREE
Cardiology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
ESC 2025 Interview: Thomas F. Lüscher
6
Mins
September 2025
First of all, the pioneers started the ESC 75 years ago. These were mainly colleagues from Sweden, France, Germany, and the UK…
Read more
6
Mins
22 Sep 2025
ESC 2025 Interview: Thomas F. Lüscher
First of all, the pioneers started the ESC 75 years ago. These were mainly colleagues from Sweden, France, Germany, and the UK…
31 Aug 2025
ESC 2025: First-Line Potential for Aficamten in Obstructive Cardiomyopathy
The MAPLE-HCM trial shows aficamten improves exercise capacity and symptoms more than metoprolol in symptomatic obstructive hypertrophic cardiomyopathy.
31 Aug 2025
ESC 2025: Starting SGLT2 Inhibitors in Hospital May Improve Heart Failure Outcomes
In-hospital initiation of SGLT2 inhibitors is safe and may lower early cardiovascular death, worsening heart failure, and mortality in hospitalised patients.
31 Aug 2025
ESC 2025: Raising Potassium Reduces Ventricular Arrhythmia Risk in High-Risk Patients
The POTCAST trial shows raising plasma potassium to high-normal levels reduces ventricular arrhythmia risk, hospitalisations, and death in ICD patients.
30 Aug 2025
ESC 2025: Digitoxin Trial Redefines Role of Glycosides in Heart Failure
DIGIT-HF shows digitoxin reduces death and hospitalisation in advanced heart failure, offering an additional option for high-risk patients on top of standard therapy.
30 Aug 2025
ESC 2025: Age Drives Arrhythmia Risk While Fitness Offers Protection
A large study finds age strongly increases arrhythmia risk, while higher fitness levels protect against atrial ectopy in asymptomatic adults.
30 Aug 2025
ESC 2025: CPR Devices Put to the Test in Zero Gravity
Automatic chest compression devices outperform manual methods for CPR in simulated zero gravity, with piston devices meeting guideline-recommended standards.
30 Aug 2025
ESC 2025: Ethnic Differences Shape Cardiovascular Outcomes in Hypertension
A major analysis finds Afro-American patients with hypertension face higher cardiovascular morbidity, while Asian patients carry a greater risk of stroke.
Loading posts...
1
2
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View